Shares of Novo Nordisk (NVO) lost 5.5% on Friday after the company announced top-line data from a mid-stage study evaluating the safety and efficacy of its investigational candidate, monlunabant (formerly INV-202), to treat obesity. The stock price is likely to have declined as the efficacy and safety results failed to impress the investors.Monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist, was added to Novo Nordisk’s clinical pipeline following the acquisition of Inversago Pha ...